Fisons Ltd.

John Mann

Thomas S Orr

David E Hall

Roger C Brown

Richard Hazard

There are described compounds of formula I, ##STR1## in which R.sub.3 represents hydrogen, or alkyl C 1 to 6,

Tricyclic mono-chromone-2-carboxylic acids

There is described a pharmaceutical composition comprising one or more of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol; 5-(2-hydroxy-propoxy)-8-propyl-chromone-2-carboxylic acid; 6,7,8,9-tetrahydro-4-oxo-10-propyl-4H-naphtho[2,3-b]pyran-2-carboxylic acid; 6,7,8,9-tetrahydro-5-hydroxy-4-oxo-10-propyl-4H-naphtho[2,3-b]pyran-2-carb oxylic acid; or a pharmaceutically acceptable salt of any one thereof, in combination with one or more of aspirin, indomethacin, phenylbutazone or oxyphenbutazone. (Mixtures of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, with aspirin or indomethacin do not form part of the invention). There are also described packages containing the separate components of the composition and pharmaceutical formulations containing the composition.

Composition

There are described compounds of formula I, ##STR1## in which R.sub.3 represents hydrogen, or alkyl C 1 to 6, R.sub.5 represents hydrogen, hydroxy, alkoxy C 1 to 6, alkanoyloxy C 2 to 6, alkenyloxy C 2 to 6, nitro, -NR.sub.1 R.sub.2, halogen, alkyl C 1 to 6, hydroxy-alkyl C 1 to 6, or hydroxy-alkoxy C 1 to 6,

There is described a pharmaceutical composition comprising one or more of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol; 5-(2-hydroxy-propoxy)-8-propyl-chromone-2-carboxylic acid; 6,7,8,9-tetrahydro-4-oxo-10-propyl-4H-naphtho[2,3-b]pyran-2-carboxylic acid; 6,7,8,9-tetrahydro-5-hydroxy-4-oxo-10-propyl-4H-naphtho-[2,3-b]pyran-2-car boxylic acid; or a pharmaceutically acceptable salt of any one thereof, in combination with one or more of aspirin, indomethacin, phenylbutazone or oxyphenbutazone. (Mixtures of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, with aspirin or indomethacin do not form part of the invention). There are also described packages containing the separate components of the composition and pharmaceutical formulations containing the composition.

Composition and methods of use

There is described a pharmaceutical mixture comprising 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, and aspirin or indomethacin. The mixture causes less gastrointestinal adverse effects than aspirin or indomethacin on their own.

Growing community of inventors

Long Whatton, United Kingdom

John Mann